08.23.12
Jack V. Talley has been appointed president and chief executive officer and Enza Guagenti has been named chief financial officer of Actinium Pharmaceuticals, Inc. (API). Mr. Talley has more than 30 years of experience in marketing, drug development and regulatory matters. He was responsible for guiding two companies through the transition to becoming public reporting entities, Penwest Pharmaceuticals and EpiCept Corp., where he recently served as president and chief executive officer. He also oversaw the approval of Ceplene for the remission maintenance of acute myeloid leukemia in the EU, as well as its license and eventual sale to Meda AB.
Ms. Guagenti is a CPA with more than 25 years of experience in health care management financial oversight. Previously, Ms. Guagenti worked for API as a corporate accounting consultant. Ms. Guagenti has held senior management level positions for various companies, where she was responsible for operational and financial oversight and reporting, as well as compliance with state and federal regulatory bodies. Ms. Guagenti has served as president of the NJ Assoc. of Ambulatory Surgery Centers and has served on various state healthcare committees.
Ms. Guagenti is a CPA with more than 25 years of experience in health care management financial oversight. Previously, Ms. Guagenti worked for API as a corporate accounting consultant. Ms. Guagenti has held senior management level positions for various companies, where she was responsible for operational and financial oversight and reporting, as well as compliance with state and federal regulatory bodies. Ms. Guagenti has served as president of the NJ Assoc. of Ambulatory Surgery Centers and has served on various state healthcare committees.